The I-OPTA Questionnaire: A National Assessment of Patients with Neovascular Age-Related Macular Degeneration.
Neovascular age-related macular degeneration
Preventive measures
Quality of life
Questionnaire
Retinal disease
Visual function
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
received:
31
07
2024
accepted:
28
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
aheadofprint
Résumé
Neovascular age-related macular degeneration (nAMD) is the leading cause of irreversible vision loss in developed countries. However, a significant gap persists in understanding this population, exacerbated by their advanced age and visual impairments, which can hinder research participation and access to healthcare. The purpose of this study was to describe the content of the questionnaire and the participating patients with nAMD. The survey includes patients diagnosed with nAMD who had previously received treatment or were currently undergoing intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections. Participants were recruited using various methods, as reaching out to patients who are no longer receiving treatment poses a particular challenge. A patient and public advisory board assisted throughout the study period. Of the 713 electronic invitations sent out, 494 (69.3%) patients responded to the questionnaire, with an additional 57 responses obtained through e-mail or telephone interviews. Due to the exclusion of 16 responses, there were a total of 535 valid responses, including 176 from patients previously treated and 359 from those currently undergoing treatment for nAMD. The median age of respondents was 79.9 years (interquartile range [IQR] 75.5-84.7), with 59.8% being women. Among them, 53.2% were married, while 43.1% lived alone. Data from the I-OPTA (Identification of Patient-Reported Barriers in Treatment for nAMD) questionnaire allows future exploration of patients who are no longer receiving treatment, patients' knowledge about preventive measures, and the impact of nAMD on visual function and quality of life. Future research, including studies that integrate data from corresponding retinal images and Danish national registers, has the potential to generate invaluable knowledge, providing benefits to both patients and healthcare professionals.
Identifiants
pubmed: 39285124
doi: 10.1007/s40123-024-01028-4
pii: 10.1007/s40123-024-01028-4
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Velux Fonden
ID : 00041038
Informations de copyright
© 2024. The Author(s).
Références
Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147–59.
doi: 10.1016/S0140-6736(18)31550-2
pubmed: 30303083
Thinggaard BS, Subhi Y, Ismail FA, Pedersen M, Morsø L, Grauslund J, Stokholm L. Factors affecting quality of life in patients with neovascular age-related macular degeneration. AJO Int. 1(3):100066. https://doi.org/10.1016/j.ajoint.2024.100066
Gale RP, Finger RP, Eldem B, Aslam T, Barratt J, Daien V, et al. The management of neovascular age-related macular degeneration: a systematic literature review of patient-reported outcomes, patient mental health and caregiver burden. Acta Ophthalmol. 2023;101(1):e26–42.
doi: 10.1111/aos.15201
pubmed: 35790079
Vu KV, Mitchell P, Detaram HD, Burlutsky G, Liew G, Gopinath B. Risk factors for poorer quality of life in patients with neovascular age-related macular degeneration: a longitudinal clinic-based study. Eye (London). 2023;37(13):2736–43.
doi: 10.1038/s41433-023-02407-0
Thinggaard BS, Pedersen F, Grauslund J, Stokholm L. Intravitreal vascular endothelial growth factor inhibitor therapy in Denmark and 5-Year projections. JAMA Netw Open. 2023;6(9):e2335148.
Frederiksen KH, Stokholm L, Möller S, Thinggaard BS, Kawasaki R, Peto T, et al. VEGF inhibition in retinal vein occlusion does not associate with cardiovascular morbidity or mortality. Ophthalmol Retina. 2023;7(8):652–60.
Thinggaard BS, Frederiksen K, Subhi Y, Möller S, Sørensen TL, Kawasaki R, et al. VEGF inhibition associates with decreased risk of mortality in patients with neovascular age-related macular degeneration. Ophthalmol Sci. 2024;4(3): 100446.
doi: 10.1016/j.xops.2023.100446
pubmed: 38313400
Subhi Y, Sørensen TL. Neovascular age-related macular degeneration in the very old (≥ 90 years): epidemiology, adherence to treatment, and comparison of efficacy. J Ophthalmol. 2017;2017:7194927.
pubmed: 28660080
pmcid: 5474234
Thinggaard BS, Pedersen M, Sorensen TL, Grauslund J, Stokholm L. Patient perspectives and barriers in the treatment of neovascular age-related macular degeneration in Denmark: a qualitative study. BMJ Open. 2023;13(11): e077175.
doi: 10.1136/bmjopen-2023-077175
pubmed: 38016793
pmcid: 10685919
Fonteh CN, Mathias MT, Mandava N, Manoharan N, Lynch AM, Navo R, et al. Mental health and visual acuity in patients with age-related macular degeneration. BMC Ophthalmol. 2022;22(1):391.
doi: 10.1186/s12886-022-02602-9
pubmed: 36183081
pmcid: 9526530
Sørensen MS, Andersen S, Henningsen GO, Larsen CT, Sørensen TL. Danish version of Visual Function Questionnaire-25 and its use in age-related macular degeneration. Dan Med Bull. 2011;58(6):A4290.
pubmed: 21651879
Assi L, Chamseddine F, Ibrahim P, Sabbagh H, Rosman L, Congdon N, et al. A global assessment of eye health and quality of life: a systematic review of systematic reviews. JAMA Ophthalmol. 2021;139(5):526–41.
doi: 10.1001/jamaophthalmol.2021.0146
pubmed: 33576772
Schippert AC, Jelin E, Moe MC, Heiberg T, Grov EK. The impact of age-related macular degeneration on quality of life and its association with demographic data: results from the NEI VFQ-25 questionnaire in a Norwegian population. Gerontol Geriatr Med. 2018;4:2333721418801601.
pubmed: 30263908
pmcid: 6149028
Nickels S, Schuster AK, Singer S, Wild PS, Laubert-Reh D, Schulz A, et al. The National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25)—reference data from the German population-based Gutenberg Health Study (GHS). Health Qual Life Outcomes. 2017;15(1):156.
doi: 10.1186/s12955-017-0732-7
pubmed: 28789656
pmcid: 5549396
Subhi Y, Munch IC, Singh A, Sørensen TL. Physical activity benefits patients with age-related macular degeneration. Ugeskr Laeger. 2014;176(37):V12130712.
Velilla S, García-Medina JJ, García-Layana A, Dolz-Marco R, Pons-Vázquez S, Pinazo-Durán MD, et al. Smoking and age-related macular degeneration: review and update. J Ophthalmol. 2013;2013: 895147.
pubmed: 24368940
pmcid: 3866712
Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Kurinij N, et al. Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35. Ophthalmology. 2013;120(8):1604-11.e4.
doi: 10.1016/j.ophtha.2013.01.021
pubmed: 23582353
Mangione CM, Berry S, Spritzer K, Janz NK, Klein R, Owsley C, et al. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol. 1998;116(2):227–33.
doi: 10.1001/archopht.116.2.227
pubmed: 9488276
Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050–8.
doi: 10.1001/archopht.119.7.1050
pubmed: 11448327
Orr P, Rentz AM, Margolis MK, Revicki DA, Dolan CM, Colman S, et al. Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Investig Ophthalmol Vis Sci. 2011;52(6):3354–9.
doi: 10.1167/iovs.10-5645
Revicki DA, Rentz AM, Harnam N, Thomas VS, Lanzetta P. Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration. Investig Ophthalmol Vis Sci. 2010;51(2):712–7.
doi: 10.1167/iovs.09-3766
Mitchell J, Wolffsohn JS, Woodcock A, Anderson SJ, McMillan CV, Ffytche T, et al. Psychometric evaluation of the MacDQoL individualised measure of the impact of macular degeneration on quality of life. Health Qual Life Outcomes. 2005;3(1):25.
doi: 10.1186/1477-7525-3-25
pubmed: 15831093
pmcid: 1112609
Institute M. https://www.mapi-institute.com/linguistic-validation/methodology . Accessed 30 July 2024.
Borger.dk. Fritagelse fra Digital Post 2024. https://www.borger.dk/hjaelp-og-vejledning/hvad-har-du-brug-for-hjaelp-til/digital-post/fritagelse-fra-digital-post . Accessed 30 July 2024.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81.
doi: 10.1016/j.jbi.2008.08.010
pubmed: 18929686
Arnetz J, Sudan S, Goetz C, Arnetz B, Gowland L, Manji S, et al. Preliminary development of a questionnaire measuring patient views of participation in clinical trials. BMC Res Notes. 2019;12(1):667.
doi: 10.1186/s13104-019-4724-z
pubmed: 31639069
pmcid: 6805544
Meyer VM, Benjamens S, Moumni ME, Lange JFM, Pol RA. Global overview of response rates in patient and health care professional surveys in surgery: a systematic review. Ann Surg. 2022;275(1):e75–81.
doi: 10.1097/SLA.0000000000004078
pubmed: 32649458
Fern LA, Lewandowski JA, Coxon KM, Whelan J. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol. 2014;15(8):e341–50.
doi: 10.1016/S1470-2045(14)70113-5
pubmed: 24988937
Hoerger M. Participant dropout as a function of survey length in internet-mediated university studies: implications for study design and voluntary participation in psychological research. Cyberpsychol Behav Soc Netw. 2010;13(6):697–700.
doi: 10.1089/cyber.2009.0445
pubmed: 21142995
pmcid: 4367493
Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019;3(3):Cd005139.
pubmed: 30834517
Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, et al. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration—a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems. BMC Ophthalmol. 2020;20(1):294.
doi: 10.1186/s12886-020-01554-2
pubmed: 32680477
pmcid: 7368708
Jelin E, Wisløff T, Jørstad ØK, Heiberg T, Moe MC. Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study. BMJ Open Ophthalmol. 2019;4(1): e000353.
doi: 10.1136/bmjophth-2019-000353
pubmed: 31673632
pmcid: 6797267
Kubin AM, Korva-Gurung I, Ohtonen P, Hautala N. Health-related quality of life in patients with neovascular age-related macular degeneration: a prospective cohort study. J Patient Rep Outcomes. 2024;8(1):89.
doi: 10.1186/s41687-024-00775-z
pubmed: 39133415
pmcid: 11319536